A company announcement issued through GlobeNewswire on October 6 says Nox Peptides has launched two research-only products, GHK-Cu and a combination product it calls the Wolverine Stack, for Canadian laboratories and research organizations. Both are sold through the company's online catalog and, per the release, are supplied with research-use information and product documentation.

GHK-Cu is a copper-binding peptide, meaning the peptide chain holds a copper ion. The release says it has been the subject of scientific research for several decades and that researchers have investigated it in laboratory settings examining peptide biology and cellular processes.

What is in the stack

The Wolverine Stack is a combination product containing multiple peptides, including BPC-157 and TB-500. Nox Peptides frames it as a convenience for investigators studying several compounds inside one research framework, which is a reasonable thing for a supplier to offer and also, not incidentally, a bundle.

The naming is worth pausing on. "Wolverine" is not a laboratory designation, and a product branded after a comic-book healing factor is doing marketing work that the accompanying research-use language is then asked to undo.

No data accompanies the launch

This is a supply announcement, not a finding. No trial, no outcome figure, no named researcher, no published study appears anywhere in the release, and none is claimed.

That is normal for a catalog launch, but it is the detail readers should hold onto, because GHK-Cu, BPC-157 and TB-500 all circulate online with far more confident claims attached than any supplier statement supports. The release itself makes none of those claims.

The research-use language

Nox Peptides states the products are intended exclusively for research purposes and are not marketed as a medication or treatment for human use. The release adds that they are not intended for human or veterinary use, or for the diagnosis, treatment, prevention or cure of any disease.

Responsibility is pushed to the buyer. The company says researchers and organizations must ensure that purchasing, storage, handling and use comply with applicable Canadian laws, institutional policies and laboratory protocols, and encourages them to review specifications, batch information, certificates of analysis and storage requirements before use.

Bottom line

What happened here is that two more peptides became easier to buy in Canada, with documentation attached. The evidence base for any of them was not changed by the announcement, and the release does not pretend otherwise.